[Evaluation of cis-diamminedichloroplatinum (II) in the multidisciplinary treatment of head and neck cancers].
Thirty-eight cases of head and neck cancer treated with cis-diamminedichloroplatinum (II) (CDDP) with/without the combination of Peplomycin (PEP) from 1982 to 1985 were evaluated. The overall response rate was 55%. Eleven of 16 patients who had received no prior therapy obtained CR and 4 patients obtained PR, the response rate being 94%. In contrast, only 6 of 22 patients who had been previously treated achieved CR and PR, the response rate being 27%. According to the pharmacokinetics of CDDP and clinical observation of measurable recurrent tumors after the administration of CDDP alone, it was revealed that the volume of CDDP-sensitive and-resistant cells were balanced at 3 weeks after the injection of CDDP. After this time, CDDP-resistant cells exceeded CDDP-sensitive cells in volume. From viewpoint, in the case of multidisciplinary treatment with CDDP, other therapies should be induced within 3 weeks after CDDP injection.
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D008875:Middle Aged
D002945:Cisplatin